Physician

Hemang U Dave, M.D.

According to 2025 Medicare claims, Hemang Dave, M.D. (NPI: 1891782371) practices hematology/oncology in the Atlantic City-Hammonton, NJ market, with the plurality of this provider's patient population coming from Cape May, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08210-2122.

Dave's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 687 traditional Medicare patients, billed 134,339 HCPCS/CPT codes, and received $1,873,653 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 835 prescription claims across 173 beneficiaries totaling $3,067,479 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 28 claims. Open Payments data shows 119 records totaling $2,507. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $871,304 to $3,067,479. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	863	196,665	$1,853,530
2016	942	218,009	$1,940,857
2017	941	264,213	$2,200,373
2018	802	212,503	$2,104,111
2019	719	194,287	$2,499,991
2020	711	212,646	$2,642,953
2021	738	241,334	$2,508,469
2022	690	158,932	$2,315,841
2023	686	112,336	$1,480,039
2024	687	134,339	$1,873,653

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	177	837	$871,304
2016	174	798	$1,493,172
2017	182	781	$2,000,569
2018	165	862	$1,627,789
2019	158	732	$1,463,704
2020	168	747	$1,894,204
2021	165	757	$2,128,501
2022	154	731	$2,193,584
2023	152	690	$1,592,516
2024	173	835	$3,067,479

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	70	$45,874
2016	N/R	48	$29,729
2017	N/R	79	$12,071
2018	N/R	64	$10,692
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	28	$1,002
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	125	208	$149
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	337	541	$101
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	176	284	$13
36415	Insertion of needle into vein for collection of blood sample	460	1,178	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	492	1,272	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	34	945	$678,237
Imbruvica	Ibrutinib	50	1,446	$621,730
Zavesca	Miglustat	14	420	$293,488
Xtandi	Enzalutamide	15	450	$204,475
Eliquis	Apixaban	77	5,504	$101,466

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	119	$2,507	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hemang U. Dave, M.D.?

Tedicare shows public-source Medicare data for Hemang U. Dave, M.D. (NPI 1891782371), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hemang U. Dave, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hemang U. Dave, M.D.?

Hemang U. Dave, M.D. is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Hemang U. Dave, M.D. have Open Payments data?

Hemang U. Dave, M.D. has 119 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.